Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus
연구 개요
상태
상세 설명
Upper gastrointestinal symptoms (early satiety, pain, nausea, and vomiting) are not uncommon in diabetic (DM) enteropathy. While these symptoms are often attributed to accelerated or delayed gastric emptying, the precise contribution of abnormal gastric emptying to symptoms in patients with DM gastroparesis is often unclear.
The investigators recently observed that approximately 50% of patients with functional dyspepsia have increased sensation to duodenal nutrient (carbohydrate and lipid) perfusion. Another recent study suggests that patients with functional dyspepsia have low-grade mucosal inflammation, abnormalities of cell-to-cell adhesion proteins which predispose to increased epithelial permeability, and a leaky epithelial barrier. Type 1 DM is associated with increased small intestinal permeability even in subjects who do not have celiac disease.
Hence, the investigators proposed to evaluate the overall hypothesis that intestinal chemosensitivity related to increased epithelial permeability and GLP-1 explains symptom severity in patients with functional dyspepsia and in patients with DM and dyspepsia. Healthy subjects, Patients with DM and GI symptoms, and patients with functional dyspepsia underwent assessment of intestinal chemosensitivity during duodenal nutrient perfusion, gastric emptying (by scintigraphy), cardiovascular and GI vagal functions (plasma pancreatic polypeptide response to sham feeding and a comprehensive autonomic reflex screen), in vivo assessment of small intestinal permeability (urinary lactulose:mannitol ratio), and upper endoscopy with assessment of epithelial tight junction proteins and permeability on small bowel biopsies.
During the nutrient infusion, subjects in each group (i.e., healthy subjects, functional dyspepsia and DM) were randomized to lipid infusion and placebo or lipid infusion and exendin 9-39. Hormonal responses (i.e., GLP-1, cholecystokinin (CCK), gastric inhibitory polypeptide (GIP), glucagon, peptide tyrosine tyrosine (PYY), C-peptide, and insulin) and plasma glucose will also be evaluated during enteral nutrient infusion. GI symptoms during each perturbation (meal, nutrient infusion) will be evaluated by validated questionnaires. Blood will be collected for DNA-based genetic analyses, initially to assess the relationship of GI sensorimotor dysfunctions and symptoms with single nucleotide polymorphisms (SNPs) affecting CCK and GLP-1 receptors. The analysis will assess for disturbances in these parameters in functional and DM dyspepsia, investigate associations between symptoms during enteral infusion and hormonal-epithelial functions, and evaluate relationships between daily symptoms and results of testing.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55905
- Mayo Clinic in Rochester
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion criteria for controls:
- Healthy male or non-pregnant, non-breastfeeding female volunteers;
- 18-70 years old;
- Able to provide written informed consent before participating in the study;
- Able to communicate adequately with the investigator and to comply with the requirements for the entire study
Additional inclusion criteria for patients:
- Symptoms of dyspepsia (i.e., early satiety, postprandial discomfort, nausea, vomiting, regurgitation)
- Patients in the Diabetes Mellitus (DM) group will also require Type 1 or 2 DM of ≥ 3 years duration; in patients with type 2 DM, the dyspepsia symptoms should have begun or worsened after DM was diagnosed
Exclusion criteria - for patients and controls:
- Major abdominal surgery (i.e., appendectomy, cholecystectomy, tubal ligation, hysterectomy, and limited colonic resection are permissible)
- Clinical evidence (including physical exam and EKG) of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric or other disease that may interfere with the objectives of the study and/or pose safety concerns
- Opiates, alpha adrenergic agonists, metoclopramide, and high doses of anticholinergic agents (e.g., amitriptyline greater than 50 mg daily). If medically safe, these drugs may be discontinued for four half lives prior to study assessments
- Treatment with glucagon-like peptide-1 (GLP-1) agonists and amylin which cause vagal blockade and may affect central processing of pain
- Use of tobacco products within the past six months or NSAIDs or aspirin within the past week (since they all may affect intestinal permeability)
- Bleeding or clotting disorders or medications that increase risk of bleeding from mucosal biopsies
- Positive tissue transglutaminase antibodies (TTG)
- For two days prior to studies, subjects will be instructed to avoid ingestion of artificial sweeteners such as sucralose (SplendaTM), aspartame (NutrasweetTM), foods containing lactulose or mannitol
- Pregnant or breast-feeding females
- Known intolerance or allergy to eggs
- Poor peripheral venous access, if central venous access is not available
- Any other condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study
Exclusion criteria for controls only:
• Current symptoms of a functional gastrointestinal disorder assessed by questionnaire
Exclusion criteria for patients only:
- Severe vomiting that would preclude tube placement or participation in the study
- Structural cause for symptoms by endoscopy within the past 48 months
- Patients with gastric pacemakers
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Healthy Controls Exendin 9-39
Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min). Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml). |
Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
|
|
위약 비교기: Healthy Controls Placebo
Normal saline infusion was prepared to match the appearance of Exendin 9-39.
Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
|
Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
Normal saline infusion will be prepared to match the appearance of Exendin 9-39
|
|
실험적: Diabetics Exendin 9-39
Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min). Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml). |
Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
|
|
위약 비교기: Diabetics Placebo
Normal saline infusion was prepared to match the appearance of Exendin 9-39.
Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
|
Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
Normal saline infusion will be prepared to match the appearance of Exendin 9-39
|
|
실험적: Functional Dyspepsia Exendin 9-39
Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min). Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml). |
Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
|
|
위약 비교기: Functional Dyspepsia Placebo
Normal saline infusion was prepared to match the appearance of Exendin 9-39.
Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
|
Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
Normal saline infusion will be prepared to match the appearance of Exendin 9-39
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Mean Intestinal Chemosensitivity to Lipids Perfusion
기간: Day 1, approximately 2 hours after infusion
|
Intestinal chemosensitivity was recorded by evaluating symptoms during duodenal lipid infusion (0.5 gm/mL diluted in water to 222 mL) and placebo or the glucagon like peptide 1 (GLP-1) receptor antagonist exendin 9-39 over 2 hours.
Participants reported the severity of 6 symptoms (nausea, fullness, bloating, abdominal pain, belching, and burning) at 15 minute intervals using a Visual Analogue Scale (VAS) marked 0 (minimum value) - 4 (maximum value): absent (0), light (1), moderate (2), severe (3) and intolerable(4).
The scores recorded for nausea, fullness, bloating, and abdominal pain over the 2 hour infusion were averaged and reported as the mean symptom score.
Higher scores mean a worse outcome.
|
Day 1, approximately 2 hours after infusion
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Rate of Gastric Emptying (GE t 1/2) in Patients With Diabetes Mellitus (DM) or Non-ulcer Dyspepsia (NUD) Compared to Placebo
기간: Day 1
|
The time for half of the ingested solids or liquids to leave the stomach.
Following a meal consisting of two eggs labeled with technetium Tc 99m sulfur colloid (1 mCi) served on one slice of bread with milk labeled with indium In111 diethylenetriaminepentaacetate (0.1 mCi), gastric emptying of solids and liquids was assessed with scintigraphy.
Rapid emptying is defined as ≥ 36% emptied at one hour and delayed emptying is defined as < 76% emptied at four hours.
Normal emptying is defined as amount less than rapid emptying definition but greater than delayed emptying definition.
|
Day 1
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Adil Bharucha, MBBS, MD, Mayo Clinic
간행물 및 유용한 링크
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Exendin 9-39에 대한 임상 시험
-
Amylyx Pharmaceuticals Inc.사용 가능
-
The University of Texas Health Science Center at...모병
-
University Hospital, Gentofte, CopenhagenUniversity of Copenhagen완전한
-
University Hospital, Gentofte, CopenhagenUniversity of Copenhagen완전한
-
Diva De LeonNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institutes...완전한